Vibrant Therapeutics, a clinical-stage biotechnology company specialising in intelligent therapeutics, has appointed Han Lee as co-CEO.
Lee brings over 15 years of expertise in leadership to his new role at Vibrant. He most recently served as President and CFO of ImmPACT Bio. During this time, he supported ImmPACT’s acquisition by Lyell Immunopharma. He has also held the role of CFO at Neogene Therapeutics and Arcellx. He has served on the Boards of DeciBio and Century Therapeutics.
Additionally, Lee led Corporate Development and Ventures at AstraZeneca, including financings, mergers, acquisitions and partnerships.
In his new role as co-CEO of Vibrant, Lee will assist with the development of the company’s lead programme, VIB305, an oncology drug designed to target tumours while sparing healthy tissues.
Lee said: “Vibrant has built a differentiated platform that combines intelligent molecular design with disease-selective biology.”
He added that he hoped “to help scale the organisation globally” and create “meaningful impact for patients”.